Industry news that matters to you.  Learn more

Archives for January 2011

CXCL10 is a Negative Prognostic Biomarker of Viral Clearance in Chronic HCV Patients

French researchers recently analyzed chronic hepatitis C virus (HCV) patients to identify plasma biomarkers for response to therapy. They identified CXCL10 as a negative prognostic biomarker of viral clearance.

Takeda Pharmaceutical Licenses Predictive Alzheimer’s Biomarker from Zinfandel

Takeda Pharmaceutical Company recently announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel Pharmaceutical’s TOMM40 assay as a biomarker for the risk of Alzheimer’s disease.

OPKO Health Identifies Alzheimer’s Diagnostic Markers, Collaborates with Bristol-Meyers Squibb

Earlier this month, OPKO Health announced the publication (link below) of a powerful method for the identification in small blood samples of disease-specific antibodies that can serve as diagnostic biomarkers. They also reported on the discovery of two antibodies unique to patients with Alzheimer’s disease.

Qiagen Acquires a Minority Stake in Alacris’ Biomarker Pipeline

Qiagen has announced that it is acquiring a minority stake in Alacris Theranostics GmbH, a German start-up company that uses novel technologies to develop individualized cancer treatment strategies based upon a patient’s genomic profile.

UConn Cardiologists Identify Predictive Biomarker of Heart Attack

Cardiologists at the University of Connecticut Health Center have identified a predictive serum biomarker for myocardial infarction. The biomarker, a cleaved p17 fragment (p17) of caspase-3 (Casp3), was detected using an enzyme-linked immunosorbent assay (ELISA).